CellVir

company

About

CellVir develops anti-retrovirals treatments focused on HIV-1 and the viral replication in infected cells.

  • 1 - 10

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$387K
Industries
Biotechnology
Founded date
Mar 1, 2006
Number Of Employee
1 - 10
Operating Status
Active

CellVir, founded in March 2006, is developing a new generation of anti-retrovirals based on a novel therapeutic mode of action. Instead of targeting the inhibition of the catalytic activity of viral enzymes (as do most of today's drugs), CellVir's approach targets host-virus protein-protein interactions which have been shown to be essential for viral replication in infected cells. Drugs operating via this novel mode of action offer two key potential advantages: complementarity to existing drugs because of their lack of susceptibility to cross resistance mechanisms, and a reduced occurrence of viral mutations that lead to drug resistance.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$387K
CellVir has raised a total of $387K in funding over 2 rounds. Their latest funding was raised on Jun 16, 2008 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 16, 2008 Series Unknown $387K 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
CellVir is funded by 2 investors. Inserm Transfert Initiative and Genopole are the most recent investors.
Investor Name Lead Investor Funding Round
Inserm Transfert Initiative Series Unknown
Genopole Series Unknown